Cancer Immunotherapy: A Treatment for the Masses
Top Cited Papers
- 9 July 2004
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 305 (5681), 200-205
- https://doi.org/10.1126/science.1100369
Abstract
Cancer immunotherapy attempts to harness the exquisite power and specificity of the immune system for the treatment of malignancy. Although cancer cells are less immunogenic than pathogens, the immune system is clearly capable of recognizing and eliminating tumor cells. However, tumors frequently interfere with the development and function of immune responses. Thus, the challenge for immunotherapy is to use advances in cellular and molecular immunology to develop strategies that effectively and safely augment antitumor responses.Keywords
This publication has 42 references indexed in Scilit:
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T CellsThe Journal of Experimental Medicine, 2004
- γδ T cells for immune therapy of patients with lymphoid malignanciesBlood, 2003
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002
- Mobilization of Dendritic Cell Precursors in Patients With Cancer by Flt3 Ligand Allows the Generation of Higher Yields of Cultured Dendritic CellsJournal of Immunotherapy, 2002
- Chemokines: agents for the immunotherapy of cancer?Nature Reviews Immunology, 2002
- Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte ResponsesThe Journal of Experimental Medicine, 2001
- Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma VaccineThe Journal of Experimental Medicine, 2001
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996
- Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor AntigensScience, 1994